论文部分内容阅读
目的探讨培美曲塞单药治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法 28例年龄>70岁的老年晚期NSCLC患者接受培美曲塞500mg/m2静脉滴注,第1天,每3周重复。2周期后评价疗效。结果 28例患者中获得CR0例,PR4例,SD11例,PD13例,总有效率为(CR+PR)为14.28%,临床获益率(CR+PR+SD)为53.57%。经治疗后患者的KPS评分从72.5上升到84.2(P<0.05)。毒副反应轻,可以耐受。结论培美曲塞单药治疗老年晚期NSCLC是安全有效的,并能改善生活质量,患者耐受性好。
Objective To investigate the clinical efficacy and safety of pemetrexed monotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Twenty-eight elderly patients with advanced NSCLC over 70 years of age received intravenous pemetrexed 500 mg / m2, and were repeated on the first day and every third week. After 2 cycles evaluation of efficacy. Results CR0, PR4, SD11 and PD13 were obtained in 28 patients. The total effective rate was (CR + PR) 14.28%. The clinical benefit rate (CR + PR + SD) was 53.57%. After treatment, the KPS score increased from 72.5 to 84.2 (P <0.05). Toxic side effects, can be tolerated. Conclusion Pemetrexed monotherapy for elderly patients with advanced NSCLC is safe and effective, and can improve the quality of life, patients are well tolerated.